Suppr超能文献

慢性肾脏病骨质疏松症的诊断、评估与管理:探索治疗方法——印度共识声明

Diagnosis, evaluation and management of osteoporosis in chronic kidney disease: navigating treatment approaches - Indian consensus statement.

作者信息

Kher Vijay, Sharma Rajkumar, Abraham Georgi, Shah Bharat, Gang Sishir, Gulati Sanjeev, Sahay Manisha, Kothari Jatin, Kumar Bt Anil, Ramachandran Raja, Kalra Sanjay, Sahay Rakesh Kumar, Lakhani Om, Sharma Jay Kumar, Bunger Deepak, Nickolas Thomas L

机构信息

Department of Nephrology and Kidney Transplantation, Epitome Kidney Urology Institute and Lions Hospital, New Delhi, Delhi, India.

Department of Nephrology and Renal Care, Medanta Hospital, Lucknow, Uttar Pradesh, India.

出版信息

Front Nephrol. 2025 Jul 10;5:1601610. doi: 10.3389/fneph.2025.1601610. eCollection 2025.

Abstract

BACKGROUND

Managing osteoporosis (OP) in chronic kidney disease (CKD) presents significant challenges due to altered bone metabolism. Given the lack of robust clinical trial data and a notable knowledge gap exists among nephrologists regarding an optimal management in this population, an expert consensus is crucial for developing tailored management strategies. This study aimed to gather an expert opinion to bridge this gap and establish consensus recommendations on the diagnosis and management of osteoporosis in CKD patients.

METHODS

A panel of 13 Indian and 1 international experts, including nephrologists and endocrinologists, participated in a structured survey and discussion process. Thirteen Indian experts provided their opinion on key clinical issues, including screening, diagnosis, and treatment strategies for osteoporosis in CKD. Consensus was achieved in a single round of voting, and recommendations were formulated based on the level of agreement among the panelists.

RESULTS

The expert panel reached a strong consensus (80-100% agreement) on several critical recommendations. It was agreed that osteoporosis in CKD is often asymptomatic, with fragility fractures being less common, and thus, early screening using dual-energy X-ray absorptiometry (DXA) is essential. The panel emphasized the importance of evaluating bone turnover status using serum biomarkers such as bone-specific alkaline phosphatase (BSAP) and intact parathyroid hormone (iPTH) to guide treatment decisions. Tailored treatment strategies were recommended, with a judicious use of bisphosphonates and denosumab, depending on the patient's estimated glomerular filtration rate (eGFR) and bone turnover state. The management of renal osteodystrophy (ROD) was deemed necessary before addressing CKD-induced osteoporosis.

CONCLUSION

This expert consensus provides critical insights and guidance for the management of osteoporosis in CKD. The recommendations emphasize individualized treatment approaches, the importance of early screening, and the integration of multidisciplinary care. These findings aim to fill existing knowledge gaps and improve clinical outcomes for CKD patients with osteoporosis.

摘要

背景

由于骨代谢改变,慢性肾脏病(CKD)患者骨质疏松症(OP)的管理面临重大挑战。鉴于缺乏有力的临床试验数据,且肾病学家对于该人群的最佳管理存在明显的知识差距,专家共识对于制定针对性的管理策略至关重要。本研究旨在收集专家意见以弥合这一差距,并就CKD患者骨质疏松症的诊断和管理建立共识性建议。

方法

由13名印度专家和1名国际专家组成的小组,包括肾病学家和内分泌学家,参与了结构化调查和讨论过程。13名印度专家就CKD患者骨质疏松症的关键临床问题发表了意见,包括筛查、诊断和治疗策略。通过一轮投票达成共识,并根据专家小组成员的一致程度制定建议。

结果

专家小组就多项关键建议达成了强烈共识(80%-100%的一致率)。一致认为CKD患者的骨质疏松症通常无症状,脆性骨折较少见,因此使用双能X线吸收法(DXA)进行早期筛查至关重要。专家小组强调使用血清生物标志物如骨特异性碱性磷酸酶(BSAP)和完整甲状旁腺激素(iPTH)评估骨转换状态以指导治疗决策的重要性。建议采用针对性的治疗策略,根据患者的估计肾小球滤过率(eGFR)和骨转换状态明智地使用双膦酸盐和地诺单抗。在处理CKD引起的骨质疏松症之前,认为有必要对肾性骨营养不良(ROD)进行管理。

结论

这一专家共识为CKD患者骨质疏松症的管理提供了关键见解和指导。这些建议强调个体化治疗方法、早期筛查的重要性以及多学科护理的整合。这些发现旨在填补现有知识空白,改善CKD合并骨质疏松症患者的临床结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f4d/12286787/b6fda7757934/fneph-05-1601610-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验